THC Trial Cuts PTSD Nightmares in 10-Week Study

Dronabinol shows measurable benefit against PTSD-related nightmares

A randomized controlled trial published in Nature Medicine reports that dronabinol, a pharmaceutical form of delta-9-tetrahydrocannabinol (THC), reduced the frequency and intensity of nightmares in adults with post-traumatic stress disorder. The result matters because nightmares are a defining and often persistent feature of PTSD, while medication options specifically targeting them remain limited.

The study was designed as a multicenter, double-blind, randomized, placebo-controlled trial, a standard intended to reduce bias and strengthen confidence in the findings. Adults with PTSD and recurrent nightmares were assigned to receive either dronabinol or placebo once daily before bedtime for 10 weeks. The dronabinol dose ranged from 2.5 milligrams to 15 milligrams.

By the end of the study period, patients receiving dronabinol showed a significantly greater reduction in the trial’s primary endpoint than those receiving placebo. That endpoint was the change from baseline to week 10 in the CAPS-IV B2 item, a clinician-rated measure covering nightmare frequency and intensity. The reported between-group difference was minus 1.50, with a 95% confidence interval from minus 2.28 to minus 0.71. The researchers also reported an effect size of Cohen’s d = 0.65 and a P value below 0.001.

In practical terms, the trial indicates that dronabinol did more than generate a marginal statistical signal. It produced a moderate treatment effect in a symptom domain that can be especially disruptive to sleep, mental health, and daytime functioning.

What the trial included

The study randomized 171 patients in total. Their mean age was 37.9 years, with a standard deviation of 12.8 years. Women made up 79.3% of the study population. Of those randomized, 87 patients were assigned to dronabinol and 84 to placebo.

The design is notable for several reasons. First, it was placebo-controlled, which is important in psychiatric and sleep-related research where expectations can influence reported symptoms. Second, it was double-blind, meaning participants and investigators were not intended to know who received the active treatment. Third, it was multicenter, which can improve the robustness of findings compared with a single-site study.

The intervention was also administered at bedtime, aligning the treatment schedule with the symptom under study. That does not by itself prove a mechanism, but it reflects a clinically practical approach to a nighttime problem.

Efficacy came with a safety tradeoff

The same trial that found efficacy also reported a clear burden of adverse events. Among patients receiving dronabinol, adverse events occurred in 78 people, or 89.7%. In the placebo group, adverse events were reported in 64 patients, or 77.1%.

That gap does not automatically outweigh the therapeutic signal, but it does complicate the picture. Treatment discontinuation due to adverse events occurred in five patients in the dronabinol group, equal to 5.7%, and in six patients in the placebo group, or 7.2%.

More consequentially, serious adverse events were reported in seven patients receiving dronabinol, representing 8.0% of that group, while none were reported in the placebo group. The source text does not specify the nature of those serious adverse events, so the trial summary supports caution but not detailed conclusions about the specific risks involved.

That distinction matters. The study provides evidence of benefit, but it does not justify a simple narrative that the treatment is ready for broad, uncomplicated use. The authors themselves note that long-term efficacy and safety require further evaluation.

Why the finding matters now

PTSD-related nightmares remain difficult to manage, and treatment decisions often require balancing symptom relief against side effects, tolerability, and risk. A controlled trial showing significant improvement in nightmare symptoms adds important evidence to a field where pharmacological options are limited.

The findings may also influence how researchers think about symptom-targeted PTSD treatment. Rather than focusing only on broad overall symptom clusters, this study centers a particularly distressing and measurable complaint. If replicated and extended, that model could support more targeted interventions for sleep disruption within PTSD care.

At the same time, the trial leaves several questions open. The study duration was 10 weeks, which is enough to detect near-term effects but not enough to establish durability. The source text also does not describe longer-term follow-up after treatment ended. That means it remains unclear whether the benefit persists, diminishes, or requires ongoing dosing.

The sample composition also deserves attention. Because 79.3% of participants were female, clinicians and researchers will likely want to know how generalizable the results are across broader PTSD populations. That is not a flaw in itself, but it is relevant context for interpreting the evidence.

What this study does and does not establish

Based on the supplied abstract text, the study establishes that dronabinol outperformed placebo on a clinician-rated measure of nightmare frequency and intensity after 10 weeks of bedtime treatment in adults with PTSD and recurrent nightmares. It also establishes that adverse events were common in both groups and that serious adverse events occurred only in the dronabinol arm.

It does not establish long-term safety, long-term effectiveness, or a full risk-benefit profile across different patient groups. It also does not, based on the source text provided, show whether improvements in nightmares translated into broader gains in overall PTSD symptoms, quality of life, or daily functioning beyond the primary endpoint.

Still, this is a meaningful result. In a field where sleep-related PTSD symptoms can be deeply persistent and pharmacological options remain constrained, a positive randomized trial is likely to draw attention from clinicians, researchers, and regulators alike.

• The trial randomized 171 adults with PTSD and recurrent nightmares.
• Dronabinol significantly improved the primary nightmare outcome versus placebo after 10 weeks.
• Serious adverse events occurred in seven dronabinol patients and none on placebo.
• The authors said long-term efficacy and safety still need further study.

This article is based on reporting by Nature Medicine. Read the original article.